Efficacy and safety results of a prospective phase II study (IPUtrial) of inetetamab and pyrotinib in combination with utidelone for first- or second-line treatment of HER2-positive metastatic breast cancer.

Herceptin (trastuzumab) - Roche

Irene (pyrotinib) - Jiangsu Hengrui Pharma

utidelone IV (UTD1) - Beijing Biostar Technologies

Cipterbin (inetetamab) - 3SBio

https://www.asco.org/abstracts-presentations/261231

Hui Cao; Mingxi Jing; Yan Wang; Xiangyu Guo; Ying E; Cui Jiang; Li Tang; Tao Sun; Min Yan; Zhaohui Li; Li Man; Songhe Zhang; Xiujie Cui; Caiyun Zhou; Xiaorui Li

Apr 21, 2026